(Q46967291)

26 December 2017

title

Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria (English)

1 reference

26 December 2017

0 references

Tsukasa Nakamura

1

1 reference

26 December 2017

Takeshi Sugaya

2

1 reference

26 December 2017

Yasuhiro Kawagoe

3

1 reference

26 December 2017

Yoshihiko Ueda

4

1 reference

26 December 2017

Hikaru Koide

5

1 reference

26 December 2017

publication date

1 September 2006

1 reference

26 December 2017

Diabetes - Metabolism: Research and Reviews

published in

1 reference

26 December 2017

volume

22

1 reference

26 December 2017

issue

5

1 reference

26 December 2017

page(s)

385-389

1 reference

26 December 2017

Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules

cites work

1 reference

Comparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: no evidence of increased risk of liver failure with pioglitazone

21 January 2018

1 reference

7 January 2021

Effect of pioglitazone on lipids in well controlled patients with diabetes mellitus type 2 -- results of a pilot study

1 reference

7 January 2021

Effect of pioglitazone on the early stage of type 2 diabetic nephropathy in KK/Ta mice

1 reference

7 January 2021

Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients

1 reference

7 January 2021

Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients

1 reference

7 January 2021

The role of renal proximal tubular cells in diabetic nephropathy

1 reference

7 January 2021

Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

1 reference

7 January 2021

Silent cerebral infarction in patients with type 2 diabetic nephropathy. Effects of antiplatelet drug dilazep dihydrochloride

1 reference

7 January 2021

Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients

1 reference

7 January 2021

Effects of dietary treatment alone or diet with voglibose or glyburide on abdominal adipose tissue and metabolic abnormalities in patients with newly diagnosed type 2 diabetes

1 reference

7 January 2021

A single dose of nateglinide improves post-challenge glucose metabolism and endothelial dysfunction in Type 2 diabetic patients

1 reference

7 January 2021

Urinary fatty acid–binding protein as a new clinical marker of the progression of chronic renal disease

1 reference

7 January 2021

Differential effects of peroxisome proliferator activated receptor-gamma (PPAR gamma) ligands in proximal tubular cells: thiazolidinediones are partial PPAR gamma agonists

1 reference

7 January 2021

Troglitazone suppresses the secretion of type I collagen by mesangial cells in vitro.

1 reference

7 January 2021

Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts.

1 reference

7 January 2021

Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease

1 reference

7 January 2021

Pioglitazone increases renal tubular cell albumin uptake but limits proinflammatory and fibrotic responses

1 reference

7 January 2021

Proteinuria and phenotypic change of proximal tubular cells

1 reference

7 January 2021

Locations of the three primary binding sites for long-chain fatty acids on bovine serum albumin

1 reference

7 January 2021

Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators

1 reference

7 January 2021

Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial

1 reference

7 January 2021

Identifiers

DOI

10.1002/DMRR.633

1 reference

26 December 2017

PubMed ID

16506273

1 reference

26 December 2017